- Home
- KLXE vs CGTX Comparison
KLXE vs CGTX Comparison
Compare KLXE & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLXE
- CGTX
- Stock Information
- Founded
- KLXE 2018
- CGTX 2007
- Country
- KLXE United States
- CGTX United States
- Employees
- KLXE N/A
- CGTX N/A
- Industry
- KLXE Oilfield Services/Equipment
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- KLXE Energy
- CGTX Health Care
- Exchange
- KLXE Nasdaq
- CGTX Nasdaq
- Market Cap
- KLXE 35.8M
- CGTX 20.5M
- IPO Year
- KLXE N/A
- CGTX 2021
- Fundamental
- Price
- KLXE $1.87
- CGTX $0.30
- Analyst Decision
- KLXE Hold
- CGTX Strong Buy
- Analyst Count
- KLXE 1
- CGTX 5
- Target Price
- KLXE $4.50
- CGTX $5.63
- AVG Volume (30 Days)
- KLXE 276.7K
- CGTX 1.9M
- Earning Date
- KLXE 08-06-2025
- CGTX 08-07-2025
- Dividend Yield
- KLXE N/A
- CGTX N/A
- EPS Growth
- KLXE N/A
- CGTX N/A
- EPS
- KLXE N/A
- CGTX N/A
- Revenue
- KLXE $688,600,000.00
- CGTX N/A
- Revenue This Year
- KLXE N/A
- CGTX N/A
- Revenue Next Year
- KLXE $3.97
- CGTX N/A
- P/E Ratio
- KLXE N/A
- CGTX N/A
- Revenue Growth
- KLXE N/A
- CGTX N/A
- 52 Week Low
- KLXE $1.51
- CGTX $0.22
- 52 Week High
- KLXE $7.66
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- KLXE 43.11
- CGTX 48.87
- Support Level
- KLXE $1.85
- CGTX $0.25
- Resistance Level
- KLXE $2.06
- CGTX $0.33
- Average True Range (ATR)
- KLXE 0.32
- CGTX 0.03
- MACD
- KLXE -0.05
- CGTX 0.00
- Stochastic Oscillator
- KLXE 1.74
- CGTX 58.69
About KLXE KLX Energy Services Holdings Inc.
KLX Energy Services Holdings Inc is a provider of completion, intervention and production services and products to the onshore oil and gas producing regions of the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Northeast/Mid-Con region.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.